 |
인쇄하기
취소
|
Kwandong, Salvat ink agreement over OAB medicine
Kwangdong Pharmaceutical said on November 16 that it has signed a licensing agreement with Spain based Laboratorios SALVAT, S.A. (Salvat), granting the former the rights to develop, register and market Tarafenacin in Korea for overactive bladder syndrome (OAB).
Under the terms of the agreement, Kwangdong will develop and commercialize Tarafenacin in South Korea. The terms of the agreement in...
Under the terms of the agreement, Kwangdong will develop and commercialize Tarafenacin in South Korea. The terms of the agreement in...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.